NASDAQ: SLS · Health Care · Cancer drug developers

SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences develops licensed cancer drugs, led by the galinpepimut-S (GPS) vaccine for acute myeloid leukaemia and the kinase inhibitor tambiciclib (SLS009).

Our rating
Sell
12-month target
$8.77
Price, Nov 17, 2026
$19.15
Expected return, with dividend
−54%

Latest research: initiation, Nov 19, 2026Market value $3,897.6m

SLSSellTarget $8.77−54% expected

Our view, Nov 19, 2026

SELLAS’s vaccine works, but its market is too small for a $3.9bn price

SELLAS is a 13-employee biotech whose leukaemia vaccine GPS just extended survival in a Phase 3 trial, and the shares jumped 156%. The market now prices more patients than the disease provides, and we see 54% downside.

What the shares could be worth
−$18.97 down+$7.62 upToday $19.15$0.18Bad case$4.97Middle case$26.77Good caseOur target $8.77

Circle size shows how likely we think each case is. Case values are present values; the target weights all three and rolls forward 12 months at an 11.1% cost of equity. Source: Penmark Research.

Read the full report

Our numbers against analysts’

Our FY26E earnings forecast is 32% above analysts’

For FY26E we forecast earnings per share of −$0.19, against analysts’ −$0.28.

Our earnings per share forecasts against analysts’
−$0.19−$0.28FY26E−$0.48FY27E−$0.43FY28E
Our estimateAnalysts’ forecast

Earnings per share as the report gives them. Analysts’ forecast is the consensus figure in the report. Source: Penmark Research estimates.

How we value it

What would change our mind

What could prove us wrong

  • FDA requires a confirmatory trial, cutting CR2 approval odds to 40% and delaying launch to FY29E: −$0.67 a share (indicative).
  • Menin inhibitors and venetoclax combinations shrink GPS's CR2 share to 30%: −$0.58 a share (indicative).
  • Payers cap US GPS net price at $200k a year: −$0.58 a share (indicative).
What bulls get right. No approved therapy holds randomised survival proof in unfit second remission, and short interest of 28.1% can keep the shares detached from value.
Dates to watch
  1. We assume $17.00 a share for the $150m offering.

  2. SLS009 data and doctors’ and payers’ views on GPS pricing; we model $300k a year.

  3. Results for patients who had venetoclax, and whether the FDA asks for a confirmatory trial.

  4. We model $19.0m of risk-adjusted FY28E sales; analysts expect $122m.

Read the full report

Our research

Also covered in Health Care

All Health Care

Questions about SELLAS Life Sciences Group

Is SELLAS Life Sciences Group stock a buy, hold or sell?

Penmark Research rates SELLAS Life Sciences Group (SLS) Sell, with a 12-month price target of $8.77, -54% from the $19.15 share price at our latest report. We expect a total return worse than −10% over the next 12 months: a fall of more than 10%, after dividends.

What is the SLS price target?

Our 12-month price target for SELLAS Life Sciences Group is $8.77, set in our initiation of Nov 19, 2026. Our bear case values the shares at $0.18 and our bull case at $26.77. The target comes from the probability-weighted value of our bull, base and bear cases.

Will SELLAS Life Sciences Group stock go up?

Our SELLAS Life Sciences Group stock forecast is a 12-month price target of $8.77, -54% from the $19.15 share price at our latest report, which is why we rate it Sell. Our bear case puts the shares at $0.18 (-99%) and our bull case at $26.77 (+40%). No forecast is certain; the main risks are below.

What does SELLAS Life Sciences Group do?

SELLAS Life Sciences develops licensed cancer drugs, led by the galinpepimut-S (GPS) vaccine for acute myeloid leukaemia and the kinase inhibitor tambiciclib (SLS009).

What are the main risks to SELLAS Life Sciences Group stock?

  • FDA requires a confirmatory trial, cutting CR2 approval odds to 40% and delaying launch to FY29E: −$0.67 a share (indicative).
  • Menin inhibitors and venetoclax combinations shrink GPS's CR2 share to 30%: −$0.58 a share (indicative).
  • Payers cap US GPS net price at $200k a year: −$0.58 a share (indicative).

What is Penmark’s latest research on SELLAS Life Sciences Group?

Our latest report is our initiation of Nov 19, 2026, “Positive Phase 3 survival data cannot justify a $3.9bn valuation; initiate at Sell”. We initiate on SELLAS Life Sciences at Sell with an $8.77 target, 54.2% below the $19.15 close. Phase 3 REGAL met overall survival in second remission, but only about 1,700 unfit US adults enter CR2 a year, and even 100% approval odds value SLS at $6.36 a share. The price implies $4.9bn of peak US GPS sales, 3.4x our…

Sign in to Penmark